FXR is a promising therapeutic target against liver fibrosis whose enhanced SUMOylation weakens the effect of obeticholic acid (FXR receptor agonist) against hepatic stellate cell activation. This evidence concerns the gene NR1H4 and Hepatic fibrosis.